{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=33", "query": { "condition": "Leukemia, Myelogenous, Acute", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 2504, "total_pages": 251, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Myelogenous%2C+Acute&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T05:08:39.120Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00382954", "title": "Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kentucky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2004-02", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2010-09-29", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 2, "location_summary": "Lexington, Kentucky • Rochester, New York", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00382954" }, { "nct_id": "NCT02652871", "title": "LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "LY2510924", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2016-05-09", "completion_date": "2019-07-16", "has_results": false, "last_update_posted_date": "2019-11-15", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02652871" }, { "nct_id": "NCT03426605", "title": "A Study of LAM-003 in Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Oncology", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Open Label LAM-003", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IRulya Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2018-01-16", "completion_date": "2020-10-05", "has_results": true, "last_update_posted_date": "2024-05-03", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03426605" }, { "nct_id": "NCT05506956", "title": "Post-transplant Flotetuzumab for AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Flotetuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-10-20", "completion_date": "2024-06-18", "has_results": true, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05506956" }, { "nct_id": "NCT04240002", "title": "A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)" ], "interventions": [ { "name": "gilteritinib", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 9, "start_date": "2020-09-04", "completion_date": "2025-03-17", "has_results": true, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04240002" }, { "nct_id": "NCT01961765", "title": "Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2013-11", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01961765" }, { "nct_id": "NCT05101551", "title": "Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Talazoparib", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Norman J. Lacayo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 34, "start_date": "2023-02-23", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05101551" }, { "nct_id": "NCT00027872", "title": "Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Erythroid Leukemia (M6)", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Cellular Diagnosis, Adult Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "tipifarnib", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 125, "start_date": "2001-10", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2013-03-25", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027872" }, { "nct_id": "NCT03068819", "title": "Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "CIML NK Cell Infusion", "type": "DRUG" }, { "name": "CD3+ T Cell Product Infusion", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-10-23", "completion_date": "2025-06-15", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03068819" }, { "nct_id": "NCT02061800", "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia (CML)", "Acute Myelogenous Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Juvenile Myelomonocytic Leukemia (JMML)", "Acute Lymphoblastic Leukemia (ALL)", "Lymphoma (Hodgkin's and Non-Hodgkin's)" ], "interventions": [ { "name": "CliniMACS CD34+ Reagent System", "type": "DEVICE" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Diane George", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 14, "start_date": "2013-06-03", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-17T05:08:39.120Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061800" } ] }